Schrödinger, Inc. (SDGR)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Schrödinger, Inc. (SDGR) trades at $11.87 with AI Score 59/100 (Hold). Schrödinger, Inc. Market cap: $876.30M, Sector: Healthcare.
Last analyzed: Feb 9, 2026Schrödinger, Inc. (SDGR) Healthcare & Pipeline Overview
Schrödinger accelerates drug discovery and materials science innovation with its proprietary physics-based software platform, offering a unique value proposition to biopharmaceutical and industrial companies seeking to optimize research and development, although profitability remains a challenge with a negative P/E ratio.
Investment Thesis
Investing in Schrödinger presents a notable opportunity to capitalize on the growing adoption of computational methods in drug discovery and materials science. The company's physics-based software platform offers a differentiated value proposition, potentially leading to increased market share and revenue growth. While the company's current P/E ratio is negative (-5.64), reflecting a lack of profitability, the potential for significant revenue growth in the Software segment and advancements in its Drug Discovery pipeline could drive future profitability. Key catalysts include successful clinical trial outcomes for its internal drug programs and expanded adoption of its software platform by biopharmaceutical companies. The company's gross margin of 58.2% indicates strong pricing power and scalability.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.99 billion reflects investor sentiment regarding Schrödinger's growth potential.
- Gross margin of 58.2% showcases the company's ability to maintain profitability on its core software and drug discovery activities.
- Operating in two segments, Software and Drug Discovery, provides diversification and multiple avenues for revenue generation.
- Beta of 1.55 indicates higher volatility compared to the market, suggesting potential for both higher gains and losses.
- No dividend yield reflects the company's focus on reinvesting earnings for growth and development.
Competitors & Peers
Strengths
- Proprietary physics-based software platform.
- Expertise in computational chemistry and molecular simulation.
- Established relationships with leading biopharmaceutical companies.
- Growing portfolio of preclinical and clinical drug programs.
Weaknesses
- Lack of profitability (negative P/E ratio).
- High R&D expenses.
- Dependence on software licensing revenue.
- Long drug development cycles.
Catalysts
- Upcoming: Clinical trial results for internal drug programs.
- Ongoing: Expansion of software platform adoption among biopharmaceutical companies.
- Ongoing: Strategic collaborations and partnerships with industry leaders.
- Ongoing: Penetration of the materials science market.
- Ongoing: Integration of AI and machine learning into the software platform.
Risks
- Potential: Failure of clinical trials for internal drug programs.
- Potential: Competition from other drug discovery software providers.
- Potential: Changes in regulatory environment affecting drug development.
- Ongoing: High R&D expenses impacting profitability.
- Ongoing: Dependence on software licensing revenue.
Growth Opportunities
- Expansion of Software Platform Adoption: Schrödinger can drive growth by expanding the adoption of its software platform among biopharmaceutical companies and academic institutions. The market for computational drug discovery software is estimated to reach billions of dollars, and Schrödinger's differentiated technology positions it to capture a significant share. Timeline: Ongoing.
- Advancement of Internal Drug Discovery Programs: The company's internal drug discovery programs represent a significant growth opportunity. Successful clinical trial outcomes and regulatory approvals could lead to substantial revenue generation and increased shareholder value. The market for novel therapeutics is vast, offering significant potential for breakthrough therapies. Timeline: Ongoing.
- Strategic Collaborations and Partnerships: Schrödinger can leverage strategic collaborations and partnerships to expand its reach and accelerate drug discovery efforts. Collaborating with leading biopharmaceutical companies can provide access to valuable resources and expertise. Timeline: Ongoing.
- Penetration of Materials Science Market: Schrödinger's software platform has applications beyond drug discovery, including materials science. Expanding into this market can diversify revenue streams and drive growth. The materials science market is experiencing rapid innovation, creating opportunities for Schrödinger's technology. Timeline: Ongoing.
- AI and Machine Learning Integration: Integrating artificial intelligence (AI) and machine learning (ML) into its software platform can enhance its capabilities and attract new customers. AI and ML are transforming drug discovery, and Schrödinger can capitalize on this trend by incorporating these technologies into its offerings. Timeline: Ongoing.
Opportunities
- Expansion of software platform adoption.
- Advancement of internal drug discovery programs.
- Strategic collaborations and partnerships.
- Penetration of materials science market.
Threats
- Competition from other drug discovery software providers.
- Failure of clinical trials.
- Changes in regulatory environment.
- Economic downturn affecting R&D spending.
Competitive Advantages
- Proprietary physics-based software platform.
- Expertise in computational chemistry and molecular simulation.
- Established relationships with leading biopharmaceutical companies.
- Growing portfolio of preclinical and clinical drug programs.
About SDGR
Schrödinger, Inc., founded in 1990 and headquartered in New York City, is transforming the way therapeutics and materials are discovered. The company offers a sophisticated physics-based software platform that empowers scientists to design novel molecules with greater precision and efficiency. Schrödinger operates through two primary segments: Software and Drug Discovery. The Software segment generates revenue by selling licenses to its software suite, which is utilized by biopharmaceutical companies and those in the materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, both internally and through collaborations with other organizations. Schrödinger's software is used for a wide range of applications, including lead identification, lead optimization, and materials design. The company serves a global clientele, including biopharmaceutical and industrial companies, academic institutions, and government laboratories. Schrödinger's integrated approach, combining advanced software with internal drug discovery efforts, positions it as a key player in the evolving landscape of computational drug discovery.
What They Do
- Develops physics-based software for drug discovery.
- Offers software solutions for materials science applications.
- Builds a portfolio of preclinical and clinical drug programs.
- Collaborates with biopharmaceutical companies on drug discovery projects.
- Provides software to academic institutions and government labs.
- Enables the design of novel molecules for therapeutic purposes.
- Offers solutions for lead identification and optimization.
Business Model
- Software licensing fees for its physics-based platform.
- Revenue from collaborative drug discovery programs.
- Potential revenue from the sale of internally developed drugs.
- Grants and funding from research institutions.
Industry Context
Schrödinger operates within the healthcare information services industry, which is experiencing rapid growth driven by advancements in technology and increasing demand for efficient drug discovery methods. The market is competitive, with companies like ABCL, AZTA, EVO, IMNM, and OMCL vying for market share. Schrödinger's physics-based software platform differentiates it from competitors, offering a unique approach to molecular design and simulation. The industry is characterized by high R&D spending and long development cycles, but the potential rewards for successful drug discovery are substantial.
Key Customers
- Biopharmaceutical companies
- Industrial companies in materials science
- Academic institutions
- Government laboratories
Financials
Chart & Info
Schrödinger, Inc. (SDGR) stock price: $11.87 (+0.00, +0.00%)
Latest News
-
Earnings Scheduled For February 25, 2026
benzinga · Feb 25, 2026
-
Top 3 Health Care stocks That Could Lead To Your Biggest Gains In Q1
benzinga · Feb 19, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SDGR.
Price Targets
Consensus target: $18.00
MoonshotScore
What does this score mean?
The MoonshotScore rates SDGR's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Common Questions About SDGR
What does Schrödinger, Inc. do?
Schrödinger, Inc. is a company that develops and sells a physics-based software platform used for drug discovery and materials science. Their software enables scientists to design novel molecules with greater precision and efficiency. In addition to their software business, Schrödinger also has a drug discovery segment where they are building a portfolio of preclinical and clinical programs, both internally and through collaborations. They serve biopharmaceutical companies, industrial companies, academic institutions, and government laboratories worldwide.
Is SDGR stock worth researching?
SDGR stock presents a mixed investment picture. The company's innovative software platform and growing drug discovery pipeline offer significant growth potential. However, the company's negative P/E ratio (-5.64) and lack of profitability raise concerns. Investors should carefully consider the company's growth prospects, competitive landscape, and financial performance before making an investment decision. Successful clinical trial outcomes and increased software adoption could drive future stock appreciation.
What are the main risks for SDGR?
Schrödinger faces several key risks. The failure of clinical trials for its internal drug programs could significantly impact its valuation. The company also faces intense competition from other drug discovery software providers. Changes in the regulatory environment could also affect its ability to develop and commercialize new drugs. Additionally, the company's high R&D expenses and dependence on software licensing revenue pose ongoing financial risks.
What are the key factors to evaluate for SDGR?
Schrödinger, Inc. (SDGR) currently holds an AI score of 59/100, indicating moderate score. Analysts target $18.00 (+52% from $11.87). Key strength: Proprietary physics-based software platform.. Primary risk to monitor: Potential: Failure of clinical trials for internal drug programs.. This is not financial advice.
How frequently does SDGR data refresh on this page?
SDGR prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven SDGR's recent stock price performance?
Recent price movement in Schrödinger, Inc. (SDGR) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. The current analyst target of $18.00 implies 52% upside from here. Notable catalyst: Proprietary physics-based software platform.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider SDGR overvalued or undervalued right now?
Determining whether Schrödinger, Inc. (SDGR) is overvalued or undervalued requires examining multiple metrics. Analysts target $18.00 (+52% from current price), suggesting analysts see upside potential. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying SDGR?
Before investing in Schrödinger, Inc. (SDGR), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data may be slightly outdated.
- AI insight pending update.